China has granted conditional commercial approval for two COVID-19 vaccines, and six of 16 vaccines given emergency permission for clinical trials have entered Phase 3 trials, the National Medical Products Administration (NMPA) said Friday.

A staff member checks the packaging quality of COVID-19 inactivated vaccine products at a packaging plant of the Beijing Biological Products Institute Co., Ltd. in Beijing, capital of China, Dec. 25, 2020. (Photo: Xinhua)

The regulatory body said it has given conditional commercial approval for two drugs and permitted clinical trials of 22 drugs for treating and preventing COVID-19 and related indications.

The NMPA has also issued emergency authorization to 54 test reagents for the novel coronavirus. It said China has reached a daily capacity of manufacturing reagents to test over 24 million people.